Molecular methods for the detection of tcd region/gene in toxigenic C. difficile are commercially available. Results can be read in as little as two to three hours after collection. FDA-approved PCR assays are highly sensitive and specific. Initial studies suggest increased sensitivity over any other available test except culture. Caution is advised when interpreting these tests as individuals who are asymptomatic may test positive for C. difficile.
These methods have relatively rapid turnaround times. Although molecular methods require expensive instrumentation and personnel with the training to correctly perform the techniques, more laboratories are investigating this avenue of diagnostic testing.
